肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

METTL3抑制剂sTC-15治疗急性髓细胞性白血病

2020-10-24 Allan MedSci原创

急性髓细胞性白血病急性髓细胞性白血病（AML）sTC-15METTL3抑制剂
关注

sTC-15是一种口服型小分子METTL3抑制剂，用于治疗急性髓细胞性白血病以及其他实体瘤和血液癌症。

急性髓细胞性白血病（AML）是成人中最常见的白血病类型，但它可影响各个年龄段的人群。有时，AML由用于治疗另一种癌症的化疗或放疗所引起。在AML中，未成熟的白血病细胞在骨髓中迅速聚集，破坏和替代了正常造血细胞。白血病细胞被释放到血流中并转运至其他器官，它们在那里继续生长和分裂。

剑桥大学的衍生公司STORM Therapeutics宣布，其一流的METTL3抑制剂已进入临床试验阶段。sTC-15是一种口服型小分子METTL3抑制剂，用于治疗急性髓细胞性白血病以及其他实体瘤和血液癌症。

该公司利用其药物发现能力，以及专门针对RNA表观遗传学开发的分析技术，来生成高效的METTL3和其他RNA修饰酶的选择性小分子抑制剂。

STORM Therapeutics首席执行官Keith Blundy说：“sTC-15是一种高效且选择性的METTL3抑制剂，急性髓细胞性白血病患者将被纳入最初的临床试验中”。

 

原始出处：

http://www.pharmatimes.com/news/storm_therapeutics_mettl3_inhibitor_moves_closer_to_the_clinic_1354586

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-04-28 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-01-20 liuxiaona

    #Mettl3#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-08-12 lqrandywkz

    #细胞性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-01-18 一闲

    #MET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-26 chengjn

    #髓细胞#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-26 12498adam42暂无昵称

    #急性髓细胞性白血病#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1852520, encodeId=f1211852520b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 28 07:06:30 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952289, encodeId=b286195228942, content=<a href='/topic/show?id=d11d1162e58' target=_blank style='color:#2F92EE;'>#Mettl3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11627, encryptionId=d11d1162e58, topicName=Mettl3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Jan 20 04:06:30 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805191, encodeId=197d180519118, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Thu Aug 12 08:06:30 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896767, encodeId=0c5a1896e676f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jan 18 11:06:30 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468219, encodeId=9c1814682197f, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481446, encodeId=fc50148144601, content=<a href='/topic/show?id=621b5248e7c' target=_blank style='color:#2F92EE;'>#急性髓细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52487, encryptionId=621b5248e7c, topicName=急性髓细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20f37789599, createdName=12498adam42暂无昵称, createdTime=Mon Oct 26 11:06:30 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894186, encodeId=a6668941866f, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Oct 24 20:15:49 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 医鸣惊人

    认真学习了

    0

相关资讯

FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）

急性髓细胞性白血病（AML）是中性粒细胞、嗜碱性粒细胞、嗜酸性粒细胞和单核细胞的前体细胞恶变并快速替代骨髓正常细胞的一种危及生命的疾病。虽然AML是成人中最常见的白血病类型，但它可影响各个年龄段的人群

Lancet Oncol：Tosedostat可有效治疗复发或难治性急性髓细胞性白血病老年患者

治疗组患者的总体生存期的Kaplan-Meier曲线 Tosedostat是一种新型的口服氨基肽酶抑制剂，既往研究已证实其在复发或难治性急性髓细胞性白血病老年患者中的临床作用。来自美国休斯敦 Anderson 肿瘤中心的Jorge Cortes等的这一研究旨在比较两种不同剂量的Tosedostat治疗方案对上述患者的疗效，他们的研究结果发表在Lancet Oncol 3月最新的在线期刊上。

Lancet Oncol：治疗急性髓细胞性白血病，索拉非尼已初见成效

来自非随机试验的临床前的数据和结果表明，多激酶抑制剂索拉非尼可能是一种有效的药物用于治疗急性髓细胞性白血病的治疗。研究人员调查了除了标准化疗，索拉非尼与安慰剂的疗效性和耐受性，参与者为年龄在60岁或以下的急性髓细胞性白血病患者。这项随机，双盲，安慰剂对照，2期临床试验已经在德国的25个站点完成。研究人员招募了年龄在18-60岁初诊，以前没有治疗过急性髓性白血病，且世界卫生组织临床性能得分0-2，有

Leukemia：中国科研人员发现治疗白血病新型抑制剂

记者6月19日从中国科学院强磁场科学中心获悉，该中心研究人员研发出一种新型白血病抑制剂CHMFL-FLT3-165，且具有自主知识产权。在临床动物模型实验中，该抑制剂可以减缓FLT3-ITD阳性急性髓细胞性白血病肿瘤在小鼠体内的增长。 该研究成果近日在线发表在国际著名学术期刊《白血病》上，并分别申请了中国发明专利和国际PCT专利申请的保护。 急性髓细胞性白血病(AML)是成年人血液系统常见的恶

FDA授予Precigen公司的非病毒多基因CAR-T疗法PRGN-3006孤儿药指定，用于治疗急性髓细胞性白血病

美国食品和药物管理局（FDA）已将PRGN-3006授予孤儿药指定（ODD），PRGN-3006是使用Precigen的非病毒UltraCAR-T平台开发的多基因CAR-T细胞治疗方法，利用先进的非病毒基因递送系统共表达嵌合抗原受体、膜结合白介素15（mbIL15）和杀伤开关，以实现更好的精确度和控制，用于复发性或难治性急性髓细胞性白血病（AML）和高危骨髓增生异常综合症（MDS）。

Cell：复旦大学研究院解析骨髓造血关键蛋白TET2三维结构

复旦大学生物医学研究院研究员徐彦辉课题组经4年多研究，首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构。该成果对研究多种疾病的发病机制，尤其对血液肿瘤（如髓系白血病）治疗性药物开发有重大意义。相关论文日前在线发表在国际学术期刊《细胞》杂志上。 哺乳动物TET蛋白家族有3个成员，即TET1蛋白、TET2蛋白和TET3蛋白，在哺乳动物发育和骨髓造血等关键生命过程

拓展阅读

Nat Commun：NPM1突变的急性髓细胞性白血病独特亚型的生物学和治疗意义

急性髓细胞性白血病（AML）作为一种遗传和生物学异质性疾病，其特征是突变型造血干细胞和祖细胞的克隆扩增和分化受损。

ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）

该研究评估了CDK9抑制剂alvocidib联合阿糖胞苷和米托蒽醌治疗复发/难治性MCL-1依赖性急性髓细胞白血病（AML）患者的有效性。

BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）

近日，FDA已批准Venclexta（venetoclax）与阿扎胞苷、地西他滨或低剂量阿糖胞苷（LDAC）的组合，用于治疗75岁以上老年初治急性髓细胞性白血病（AML）患者。